Interventions of Interest:

  • casirivimab/imdevimab (Ronapreve™, Regeneron)
  • sotrovimab (GlaxoSmithKline and Vir Biotechnology)
  • molnupiravir (Merck)
  • PF-07321332/ritonavir (PAXLOVID™, Pfizer)
  • fluvoxamine (Investigator initiated)

ICER is currently conducting a special assessment of outpatient treatments for COVID-19. COVID-19 is an infectious respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. As of August 2021, there have been over 35 million confirmed COVID-19 cases and 600,000 COVID-19 deaths in the United States (US). The direct medical costs of health care utilization from COVID-19, while substantial (>$100 billion over the expected course of the pandemic) are overshadowed by the costs of reduced economic output (>$7 trillion). Further, COVID-19 has uneven clinical and economic impacts as older individuals, those living with comorbidities, and Black and Hispanic populations are at higher risk of infection, hospitalization, and mortality while younger individuals, women, and Hispanics are at higher risk of unemployment.

For questions, please contact Laura Cianciolo, Program Manager, at lcianciolo@icer.org.

View the Key Stakeholders List.